Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 11/20 | 0.52 |
| ▸ | GSK3B | P49841 | 11/20 | 0.52 |
| ▸ | HTR1F | P30939 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | WNT1 | P04628 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12011631 | 0.87 | SMN1; SMN2 (0.49) | DYRK1AGSK3BDYRK1BABL1MAPT | |
| SCHEMBL12011572 | 0.84 | DYRK1A (0.49) | DYRK1AGSK3BDYRK1BKDM4EMAPT | |
| SCHEMBL15308629 | 0.84 | NPSR1 (0.51) | DYRK1AGSK3BDYRK1BKDM4EMAPT | |
| SCHEMBL10131077 | 0.84 | DYRK1A (0.52) | DYRK1AGSK3BHTR1FPKMDYRK1B | |
| SCHEMBL12011577 | 0.83 | PTPN1 (0.51) | DYRK1ADYRK1BKDM4E | |
| SCHEMBL10131252 | 0.79 | LMNA (0.60) | PKMKDM4EMAPT | |
| SCHEMBL2218360 | 0.78 | KDM4E (0.51) | KDM4EMAPT | |
| SCHEMBL22574422 | 0.77 | ROCK2 (0.50) | — | |
| SCHEMBL17339955 | 0.77 | PKM (0.60) | DYRK1AGSK3BPKMMKNK1KDM4E | |
| SCHEMBL23501662 | 0.76 | POLB (0.47) | DYRK1AGSK3BWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2024-04-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-3915988-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BioSplice Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200190082-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10407425-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-09-10 | — | — | US | disclosed |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-10-10 | — | — | US | disclosed |
| WO-2013151708-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8450340-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450340-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| CN-102821607-A | 1H-pyrazolo [3,4-b ] pyridines and therapeutic uses thereof | SAMUMED LLC | 2012-12-12 | — | — | CN | disclosed |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011084486-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | DYRK1A 423/4885GSK3B 4/4885HTR1F 2238/4885 |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | DYRK1A 2923/4885GSK3B 1639/4885HTR1F 1010/4885 |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | DYRK1A 2923/4885GSK3B 1639/4885HTR1F 1010/4885 |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | DYRK1A 423/4885GSK3B 4/4885HTR1F 2238/4885 |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | DYRK1A 423/4885GSK3B 4/4885HTR1F 2238/4885 |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | DYRK1A 423/4885GSK3B 4/4885HTR1F 2238/4885 |
| US-20200190082-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | DYRK1A 423/4885GSK3B 4/4885HTR1F 2238/4885 |
| US-10407425-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | DYRK1A 423/4885GSK3B 4/4885HTR1F 2238/4885 |
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | DYRK1A 1848/4885GSK3B 9/4885HTR1F 293/4885 |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | DYRK1A 423/4885GSK3B 4/4885HTR1F 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.